Hutchmed's Tazemetostat Gets Conditional Approval in China for Follicular Lymphoma Treatment

MT Newswires Live03-24

Hutchmed (China) (HKG:0013) obtained conditional approval from China's National Medical Product Association for Tazemetostat as a treatment for patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutation who have received at least two systemic therapies.

Tazemetostat, sold under the brand name Tazverik, is a first-in-class methyltransferase inhibitor of EZH2. Іt is approved by the US FDA for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma, according to a Friday filing with the Hong Kong bourse.

The drugmaker's shares were down almost 3% in Monday's afternoon trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2521766513?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 14:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521766513","market":"hk","top_or_hot":-1,"title":"Hutchmed's Tazemetostat Gets Conditional Approval in China for Follicular Lymphoma Treatment","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (China) (HKG:0013) obtained conditional approval from China's National Medical Product Association for Tazemetostat as a treatment for patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutation who have received at least two systemic therapies.</p><p>Tazemetostat, sold under the brand name Tazverik, is a first-in-class methyltransferase inhibitor of EZH2. Іt is approved by the US FDA for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma, according to a Friday filing with the Hong Kong bourse.</p><p>The drugmaker's shares were down almost 3% in Monday's afternoon trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed's Tazemetostat Gets Conditional Approval in China for Follicular Lymphoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed's Tazemetostat Gets Conditional Approval in China for Follicular Lymphoma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-24 14:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Hutchmed (China) (HKG:0013) obtained conditional approval from China's National Medical Product Association for Tazemetostat as a treatment for patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutation who have received at least two systemic therapies.</p><p>Tazemetostat, sold under the brand name Tazverik, is a first-in-class methyltransferase inhibitor of EZH2. Іt is approved by the US FDA for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma, according to a Friday filing with the Hong Kong bourse.</p><p>The drugmaker's shares were down almost 3% in Monday's afternoon trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4094","symbol_name":"服装零售","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2521766513","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521766513","pubTimestamp":1742798945,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed (China) (HKG:0013) obtained conditional approval from China's National Medical Product Association for Tazemetostat as a treatment for patients with relapsed or refractory follicular lymphoma","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4094":"服装零售","BK1587":"次新股","BK1588":"回港中概股","BK1191":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","00013":"和黄医药"},"translate_title":"和黄医药的Tazemetostat在中国获得有条件批准用于滤泡性淋巴瘤治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"FL":1},"content_text":"Hutchmed (China) (HKG:0013) obtained conditional approval from China's National Medical Product Association for Tazemetostat as a treatment for patients with relapsed or refractory follicular lymphoma (FL) with EZH2 mutation who have received at least two systemic therapies.Tazemetostat, sold under the brand name Tazverik, is a first-in-class methyltransferase inhibitor of EZH2. Іt is approved by the US FDA for the treatment of certain patients with R/R FL and certain patients with advanced epithelioid sarcoma, according to a Friday filing with the Hong Kong bourse.The drugmaker's shares were down almost 3% in Monday's afternoon trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2521766513","isCrawlerRequest":true}